June 4, 2015

Eosinophilic Esophagitis Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com

RnRMarketResearch.com adds “Eosinophilic Esophagitis – Pipeline Review, H1 2015” to its store. The report provides an overview of the Eosinophilic Esophagitis’s therapeutic pipeline.

Dallas, TX (PRWEB) June 04, 2015

The report “Eosinophilic Esophagitis – Pipeline Review, H1 2015 provides comprehensive information on the therapeutic development for Eosinophilic Esophagitis. Eosinophilic esophagitis is a chronic immune system disease. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report on H1 2015 pipeline review of Eosinophilic Esophagitis with 24 market data tables and 14 figures, spread across 67 pages is available at http://www.rnrmarketresearch.com/eosinophilic-esophagitis-pipeline-review-h1-2015-market-report.html .

Companies discussed in this Eosinophilic Esophagitis – Pipeline Review, H1 2015 report include Actavis plc, DBV Technologies S.A., Dr. Falk Pharma GmbH, Lipella Pharmaceuticals, Inc., Novartis AG, Oxagen Limited, Receptos, Inc., Regeneron Pharmaceuticals, Inc., Shire Plc, Teva Pharmaceutical Industries Limited.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Drug Profiles mentioned in this report are Allergen for Milk Allergy, budesonide, budesonide, dupilumab, EUR-1100, OC-459, QAX-576, reslizumab, RPC-4046, tacrolimus liposomal.

Featured News & Press Releases covered by this report includes: Oct 03, 2014: Receptos Announces First Patient Treated With Anti-Interleukin-13 Antibody in Phase 2 Trial for Eosinophilic Esophagitis; Sep 25, 2014: Meritage Pharma Announces Positive Results of Oral Budesonide Suspension for Treatment of Eosinophilic Esophagitis in Adolescent and Adult Patients; Jul 21, 2014: High-dose fluticasone effective against eosinophilic esophagitis; May 13, 2014: DBV Technologies Announces Clinical Trial Agreement to Develop a Treatment for Milk-Induced Eosinophilic Esophagitis in Children; Aug 13, 2012: Meritage Initiates Clinical Trial Of Oral Budesonide Suspension For Adolescent And Adult Patients With Eosinophilic Esophagitis; May 10, 2011: Meritage Pharma Reports Positive Phase IIb Data For Oral Budesonide Suspension In Pediatric Patients With Eosinophilic Esophagitis; May 10, 2011: Meritage Reports Positive Phase IIb Data For Oral Budesonide Suspension In Pediatric Patients With Eosinophilic Esophagitis; Nov 23, 2009: Ception Therapeutics and Cephalon Provide Initial Results of a Phase IIb/III Study of CINQUIL in Pediatric Eosinophilic Esophagitis.

Order a purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=388761 . (This is a premium report priced at US$2000 for a single user License.)

List of Tables

Number of Products under Development for Eosinophilic Esophagitis, H1 2015 8

Number of Products under Development for Eosinophilic Esophagitis - Comparative Analysis, H1 2015 9

Number of Products under Development by Companies, H1 2015 10

Comparative Analysis by Late Stage Development, H1 2015 11

Comparative Analysis by Clinical Stage Development, H1 2015 12

Comparative Analysis by Early Stage Development, H1 2015 13

Products under Development by Companies, H1 2015 14

Eosinophilic Esophagitis - Pipeline by Actavis plc, H1 2015 15

Eosinophilic Esophagitis - Pipeline by DBV Technologies S.A., H1 2015 16

Eosinophilic Esophagitis - Pipeline by Dr. Falk Pharma GmbH, H1 2015 17

Eosinophilic Esophagitis - Pipeline by Lipella Pharmaceuticals, Inc., H1 2015 18

Eosinophilic Esophagitis - Pipeline by Novartis AG, H1 2015 19

Eosinophilic Esophagitis - Pipeline by Oxagen Limited, H1 2015 20

Eosinophilic Esophagitis - Pipeline by Receptos, Inc., H1 2015 21

Eosinophilic Esophagitis - Pipeline by Regeneron Pharmaceuticals, Inc., H1 2015 22

Eosinophilic Esophagitis - Pipeline by Shire Plc, H1 2015 23

Eosinophilic Esophagitis - Pipeline by Teva Pharmaceutical Industries Limited, H1 2015 24

Assessment by Monotherapy Products, H1 2015 25

Number of Products by Stage and Target, H1 2015 27

Number of Products by Stage and Mechanism of Action, H1 2015 29

Number of Products by Stage and Route of Administration, H1 2015 31

Number of Products by Stage and Molecule Type, H1 2015 33

Eosinophilic Esophagitis Therapeutics - Recent Pipeline Updates, H1 2015 50

Eosinophilic Esophagitis - Dormant Projects, H1 2015 58

List of Figures

Number of Products under Development for Eosinophilic Esophagitis, H1 2015 8

Number of Products under Development for Eosinophilic Esophagitis - Comparative Analysis, H1 2015 9

Number of Products under Development by Companies, H1 2015 10

Comparative Analysis by Clinical Stage Development, H1 2015 12

Comparative Analysis by Early Stage Products, H1 2015 13

Assessment by Monotherapy Products, H1 2015 25

Number of Products by Top 10 Targets, H1 2015 26

Number of Products by Stage and Top 10 Targets, H1 2015 27

Number of Products by Top 10 Mechanism of Actions, H1 2015 28

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 29

Number of Products by Top 10 Routes of Administration, H1 2015 30

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 31

Number of Products by Top 10 Molecule Types, H1 2015 32

Number of Products by Stage and Top 10 Molecule Types, H1 2015 33

Explore more reports on Therapeutics at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics .

About Us:

RnRMarketResearch.com is an online database of market research reports and offers in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offers customized market research reports for multiple industries.

For the original version on PRWeb visit: http://www.prweb.com/releases/eosinophilic-esophagitis/pipeline-review-h1-2015/prweb12764720.htm